CRMD vs PHAT: stock comparison and AI forecast
Cormedix Inc. (CRMD) and Phathom Pharmaceuticals, Inc. (PHAT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CRMD Cormedix Inc.
- Price
- $5.23 -34.0% · 6M
- Market Cap
- $408M
- P/E Ratio
- 2.6x
- Size
- small-cap
- AI Forecast
PHAT Phathom Pharmaceuticals, Inc.
- Price
- $5.08 -59.9% · 6M
- Market Cap
- $413M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- CRMD and PHAT have similar market capitalizations ($408M and $413M).
- Over the last six months CRMD returned -34.0% and PHAT -59.9%.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CRMD | PHAT |
|---|---|---|
| Market Cap | $408M | $413M |
| P/E Ratio | 2.55x | – |
| P/B Ratio | 0.88x | – |
| EPS | $2.05 | $-0.42 |
| Book Value/Share | $5.91 | – |
| Revenue/Share | $5.80 | $3.38 |
| FCF/Share | $3.21 | $-0.26 |
Profitability & Margins
| Metric | CRMD | PHAT |
|---|---|---|
| ROE | 40.6% | – |
| ROA | 20.7% | – |
| ROIC | 30.3% | -15.0% |
| Gross Margin | 90.0% | 80.7% |
| Operating Margin | 48.0% | -9.3% |
| Net Margin | 41.4% | – |
| EBT Margin | 45.0% | -31.6% |
| Tax Rate | 8.0% | – |
Financial Health
| Metric | CRMD | PHAT |
|---|---|---|
| Current Ratio | 2.56x | 1.76x |
| Quick Ratio | 2.36x | 1.72x |
| D/E Ratio | 0.96x | – |
| Financial Leverage | 1.96x | – |
| Interest Coverage | 15.2x | -0.0x |
| Working Capital | $293M | $133M |
Cash Flow
| Metric | CRMD | PHAT |
|---|---|---|
| Operating Cash Flow | $254M | -$21M |
| Free Cash Flow | $250M | -$21M |
| Capital Spending | -$4M | -$300K |
| OCF Growth YoY | 733.6% | – |
| FCF Growth YoY | 723.5% | – |
| FCF/Sales | 55.4% | -7.7% |
| CapEx/Sales | 0.8% | 0.1% |
Operational Efficiency
| Metric | CRMD | PHAT |
|---|---|---|
| Asset Turnover | 0.50x | 0.80x |
| Receivables Turnover | 2.8x | 2.5x |
| Inventory Turnover | 1.2x | 7.0x |
| Fixed Assets Turnover | 57.6x | 294.0x |
| Days Sales Outstanding | 130 days | 143 days |
| Days Inventory | 312 days | 52 days |
| Payables Period | 83 days | 76 days |
| Cash Conversion Cycle | 359 days | 119 days |
Income Statement
| Metric | CRMD | PHAT |
|---|---|---|
| Total Revenue | $452M | $275M |
| Operating Income | $217M | -$25M |
| Net Income | $187M | – |
| R&D Expense | $28M | $32M |
| SG&A Expense | $171M | $215M |
| Cost of Goods Sold | $45M | $53M |
Dividend & Shareholder Information
| Metric | CRMD | PHAT |
|---|---|---|
| Shares Outstanding | 78M | 81M |
| Net Income Growth | 265.9% | – |
| EPS Growth | 791.3% | – |
CRMD vs PHAT: stock comparison and AI forecast
Which is bigger, CRMD or PHAT?
CRMD and PHAT have similar market capitalizations ($408M and $413M).
Which stock performed better over the last six months, CRMD or PHAT?
Over the last six months CRMD returned -34.0% and PHAT -59.9%.
Which one does Intratio's AI model rank higher, CRMD or PHAT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.